Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease.

about

Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease.

Item

http://www.wikidata.org/entity/Q49315243

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Population-based cohort study ...... in inflammatory bowel disease.

@en

Population-based cohort study ...... in inflammatory bowel disease.

@nl

type

Item

label

Population-based cohort study ...... in inflammatory bowel disease.

@en

Population-based cohort study ...... in inflammatory bowel disease.

@nl

prefLabel

Population-based cohort study ...... in inflammatory bowel disease.

@en

Population-based cohort study ...... in inflammatory bowel disease.

@nl

P1476

Population-based cohort study ...... in inflammatory bowel disease.

@en

P2093

Anna Kohn

http://www.w3.org/2001/XMLSchema#string

Antonio Gasbarrini

http://www.w3.org/2001/XMLSchema#string

Marina Davoli

http://www.w3.org/2001/XMLSchema#string

Nera Agabiti

http://www.w3.org/2001/XMLSchema#string

Silvia Cascini

http://www.w3.org/2001/XMLSchema#string

P2860

Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab

Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada.

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors.

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.

Current and emerging biologics for ulcerative colitis.

Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.

Principles for modeling propensity scores in medical research: a systematic literature review.

Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.

P304

203-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CLEP.S150030

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Addis

Francesco Trotta

Riccardo Di Domenicantonio

P577

2018-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29440933

http://www.w3.org/2001/XMLSchema#string

P932

5804123

http://www.w3.org/2001/XMLSchema#string